Sonnet BioTherapeutics Holdings, Inc. (SONN): Price and Financial Metrics

Sonnet BioTherapeutics Holdings, Inc. (SONN): $1.84

0.15 (+8.55%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

F

Add SONN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#264 of 347

in industry

SONN Price/Volume Stats

Current price $1.84 52-week high $26.40
Prev. close $1.70 52-week low $1.08
Day low $1.66 Volume 6,844
Day high $1.84 Avg. volume 89,597
50-day MA $1.87 Dividend yield N/A
200-day MA $3.06 Market Cap 5.65M

SONN Stock Price Chart Interactive Chart >


Sonnet BioTherapeutics Holdings, Inc. (SONN) Company Bio


Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.


SONN Latest News Stream


Event/Time News Detail
Loading, please wait...

SONN Latest Social Stream


Loading social stream, please wait...

View Full SONN Social Stream

Latest SONN News From Around the Web

Below are the latest news stories about SONNET BIOTHERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate SONN as an investment opportunity.

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

PRINCETON, NJ / ACCESSWIRE / December 21, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on ...

Yahoo | December 21, 2023

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

PRINCETON, NJ / ACCESSWIRE / December 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs focused on oncology, announced today its financial ...

Yahoo | December 14, 2023

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Following the recent completion of a $4.55 million financing, Sonnet projects cash runway into the calendar year third quarter of 2024The company is focused on its business development initiatives and anticipates being able to provide an update in ...

Yahoo | October 31, 2023

Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?

Sonnet BioTherapeutics stock is dropping on Wednesday after the company revealed the pricing of a public offering for SONN shares.

William White on InvestorPlace | October 25, 2023

EVGO Stock Slips as TD Cowen Downgrades EVgo

EVgo stock is taking a beating on Wednesday as investors in the EV charging company deal with a downgrade and price cut.

William White on InvestorPlace | October 25, 2023

Read More 'SONN' Stories Here

SONN Price Returns

1-mo -14.02%
3-mo 32.56%
6-mo 48.39%
1-year -68.20%
3-year -99.72%
5-year -99.99%
YTD 5.75%
2023 -93.12%
2022 -80.12%
2021 -81.48%
2020 -85.46%
2019 -54.26%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!